The Altissimo Study using a TKI for nAMD
Mar 17, 2022•13 min•Ep. 47
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
We review the results of the phase I Graybug study Altissimo using sustained release tyrosinase kinase inhibitor for long term treatment of neovascular AMD with Dr. Veeral Sheth, Chicago, Illinois, Assistant Clinical Professor University of Illinois at Chicago.
For the best experience, listen in Metacast app for iOS or Android